Clinical Advisory Board

Clinical experts in Cystic Fibrosis and Clinical Research

CAB Chair

Dr. Richard B. Moss, M.D.
Professor Emeritus of Pediatrics, Lucile Salter Packard Children’s Hospital at Stanford University
Dr. Moss is the former Chief of Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship director. Dr. Moss also served as Director of the Cystic Fibrosis Center at Stanford, and site principal investigator for Cystic Fibrosis Therapeutics Development Network, where he was also the inaugural Chair of the Protocol Review Committee from 1991 to 2009.

Advisors

Dr. Jane C. Davies, M.D., FRCPCH
Professor of Paediatric Respirology and Experimental Medicine, Imperial College London and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation
Dr. Davies is the site co-PI for the European CF Society Clinical Trials Network and leads their Lung Clearance Index Core facility. She has experience in clinical trial design for both investigator-initiated and pharma-sponsored studies.

Dr. Michael R. Knowles, M.D.
Professor of Pulmonary and Critical Care Medicine, University of North Carolina (UNC), Chapel Hill
Dr. Knowles is the head of two multicenter studies, the first, Genetic modifiers of disease phenotype (severity) in cystic fibrosis lung and liver disease, which also includes a recently formed international consortium that is conducting a whole genome scan. The second is a consortium of eight North American sites studying rare genetic disorders of mucociliary clearance. Additionally, Dr. Knowles was the site Prinicpal Investigator at UNC Chapel Hill, and served on the Steering Committee, during the inception of the Cystic Fibrosis Therapeutic Development Network.

Dr. Naimish Patel
Senior Medical Director, AstraZeneca
Dr. Patel has a background in translational and clinical research with a focus on respiratory disease. In his current role as Project Leader in Respiratory, Inflammation and Autoimmunity iMed, he leads teams in the identification and development of compounds from target identification to candidate drug nomination and early clinical development of novel targets for treatment of respiratory diseases. Previously, he was Associate Medical Director at Vertex Pharmaceuticals, Inc. where he led clinical studies for CF compounds including VX-809 and VX-661. Dr. Patel trained at the Harvard Combined Program in Pulmonary and Critical Medicine and still holds a part-time faculty position at Harvard Medical School and Beth Israel Deaconess Hospital. He continues to practice Pulmonary Medicine at Beth Israel Deaconess Hospital in Boston. Dr. Patel is board certified in Pulmonary and Critical Care Medicine.
Dr. Patel received his undergraduate degree in Mechanical Engineering at Massachusetts Institute of Technology and received his M.D.,C.M. from McGill University Faculty of Medicine.

Dr. Felix A. Ratjen, M.D., Ph.D.
Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine
Dr. Ratjen co-leads the Cystic Fibrosis Centre at The Hospital for Sick Children, and is the Medical Director of the Clinical Research Unit.

Dr. Isabelle Sermet-Gaudelus, MD, Ph.D.
Professor of Pediatric Medicine, l’Hôpital Necker-Enfants Malades in Paris, France
Dr. Sermet-Gaudelus has developed and conducted several therapeutic trials for cystic fibrosis for both academic and company-initiated investigations. Her research focuses on modulation of the clinical severity of cystic fibrosis depending on fluid transfer and its therapeutic applications.

Dr. Elizabeth Tullis
Professor of Medicine at the University of Toronto
Dr. Tullis is the Director of the Toronto Adult Cystic Fibrosis Clinic at St. Michael’s Hospital, and is responsible for the care of 490 adults with CF. Dr. Tullis is the Respirology Division Head at St. Michael’s Hospital, and an Adjunct Scientist at the Keenan Research Centre of Li Ka Shing Knowledge Institute. She is also the Cystic Fibrosis Canada Chair in Adult CF Research.

Dr. Pamela L. Zeitlin, M.D., Ph.D.
Professor and Director of Pediatric Pulmonary Medicine and the Co-Director of the Cystic Fibrosis Center, Johns Hopkins University
Dr. Zeitlin’s research focuses on the role of chloride channels in inherited diseases of the respiratory tract, especially cystic fibrosis.

COMPANY